Click here to get full coverage on Should Apogee Therapeutics’ (APGE) Infrequent-Dosing AD Data and $403M Equity Raise Require Investor Action? - simplywall.st

Should Apogee Therapeutics’ (APGE) Infrequent-Dosing AD Data and $403M Equity Raise Require Investor Action?  simplywall.st

Should Apogee Therapeutics’ (APGE) Infrequent-Dosing AD Data and $403M Equity Raise Require Investor Action? - simplywall.st

Click here to get full coverage on Mizuho Initiates Coverage of Apogee Therapeutics (APGE) with Outperform Recommendation - MSN

Mizuho Initiates Coverage of Apogee Therapeutics (APGE) with Outperform Recommendation  MSN

Mizuho Initiates Coverage of Apogee Therapeutics (APGE) with Outperform Recommendation - MSN

Click here to get full coverage on Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $110.00 at Mizuho - MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $110.00 at Mizuho  MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $110.00 at Mizuho - MarketBeat

Click here to get full coverage on Apogee Therapeutics (APGE) Is Up 17.8% After $403 Million Follow-On Tied To Zumilokibart Data - Yahoo Finance

Apogee Therapeutics (APGE) Is Up 17.8% After $403 Million Follow-On Tied To Zumilokibart Data  Yahoo Finance

Apogee Therapeutics (APGE) Is Up 17.8% After $403 Million Follow-On Tied To Zumilokibart Data - Yahoo Finance

Click here to get full coverage on Apogee Therapeutics (APGE) CFO sells 2,000 shares in planned trade - stocktitan.net

Apogee Therapeutics (APGE) CFO sells 2,000 shares in planned trade  stocktitan.net

Apogee Therapeutics (APGE) CFO sells 2,000 shares in planned trade - stocktitan.net

Click here to get full coverage on APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy - Zacks Investment Research

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy  Zacks Investment Research

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy - Zacks Investment Research

Click here to get full coverage on Apogee Therapeutics (APGE) price target increased by 11.74% to 118.86 - MSN

Apogee Therapeutics (APGE) price target increased by 11.74% to 118.86  MSN

Apogee Therapeutics (APGE) price target increased by 11.74% to 118.86 - MSN

Click here to get full coverage on Fairmount Funds reveals near-10% Apogee Therapeutics (APGE) stake and 60-day lock-up - stocktitan.net

Fairmount Funds reveals near-10% Apogee Therapeutics (APGE) stake and 60-day lock-up  stocktitan.net

Fairmount Funds reveals near-10% Apogee Therapeutics (APGE) stake and 60-day lock-up - stocktitan.net

Click here to get full coverage on Assessing Apogee Therapeutics (APGE) Valuation After A Strong One Year Shareholder Return - simplywall.st

Assessing Apogee Therapeutics (APGE) Valuation After A Strong One Year Shareholder Return  simplywall.st

Assessing Apogee Therapeutics (APGE) Valuation After A Strong One Year Shareholder Return - simplywall.st

Click here to get full coverage on Biotech Apogee raises $403M after underwriters buy extra shares - stocktitan.net

Biotech Apogee raises $403M after underwriters buy extra shares  stocktitan.net

Biotech Apogee raises $403M after underwriters buy extra shares - stocktitan.net

Click here to get full coverage on Wolfe Research initiates coverage of Apogee Therapeutics (APGE) with peer perform recommendation - MSN

Wolfe Research initiates coverage of Apogee Therapeutics (APGE) with peer perform recommendation  MSN

Wolfe Research initiates coverage of Apogee Therapeutics (APGE) with peer perform recommendation - MSN

Click here to get full coverage on Vanguard disaggregates holdings; Apogee Therapeutics (NASDAQ: APGE) shows 0 shares - stocktitan.net

Vanguard disaggregates holdings; Apogee Therapeutics (NASDAQ: APGE) shows 0 shares  stocktitan.net

Vanguard disaggregates holdings; Apogee Therapeutics (NASDAQ: APGE) shows 0 shares - stocktitan.net

Click here to get full coverage on Jane Henderson sells 6,000 APGE restricted shares (NASDAQ: APGE) - stocktitan.net

Jane Henderson sells 6,000 APGE restricted shares (NASDAQ: APGE)  stocktitan.net

Jane Henderson sells 6,000 APGE restricted shares (NASDAQ: APGE) - stocktitan.net

Click here to get full coverage on Latest APGE News - Apogee Highlights Corporate Progress and Re... - stocktitan.net

Latest APGE News - Apogee Highlights Corporate Progress and Re...  stocktitan.net

Latest APGE News - Apogee Highlights Corporate Progress and Re... - stocktitan.net

Click here to get full coverage on Biotech Apogee sells 5 million shares at $70 to raise $350M - stocktitan.net

Biotech Apogee sells 5 million shares at $70 to raise $350M  stocktitan.net

Biotech Apogee sells 5 million shares at $70 to raise $350M - stocktitan.net

Click here to get full coverage on [8-K] Apogee Therapeutics, Inc. Reports Material Event - stocktitan.net

[8-K] Apogee Therapeutics, Inc. Reports Material Event  stocktitan.net

[8-K] Apogee Therapeutics, Inc. Reports Material Event - stocktitan.net

Click here to get full coverage on Apogee Therapeutics (NASDAQ: APGE) raises $329M in 5M-share offering - stocktitan.net

Apogee Therapeutics (NASDAQ: APGE) raises $329M in 5M-share offering  stocktitan.net

Apogee Therapeutics (NASDAQ: APGE) raises $329M in 5M-share offering - stocktitan.net

Click here to get full coverage on A Look At Apogee Therapeutics (APGE) Valuation After Recent Share Price Weakness - Yahoo Finance

A Look At Apogee Therapeutics (APGE) Valuation After Recent Share Price Weakness  Yahoo Finance

A Look At Apogee Therapeutics (APGE) Valuation After Recent Share Price Weakness - Yahoo Finance

Click here to get full coverage on Mizuho Securities Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $110 - 富途牛牛

Mizuho Securities Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $110  富途牛牛

Mizuho Securities Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $110 - 富途牛牛

Click here to get full coverage on BTIG reiterates Buy on Apogee Therapeutics stock, $137 target - Investing.com

BTIG reiterates Buy on Apogee Therapeutics stock, $137 target  Investing.com

BTIG reiterates Buy on Apogee Therapeutics stock, $137 target - Investing.com

Click here to get full coverage on Wedbush Raises Price Target on Apogee Therapeutics (APGE) - Yahoo Finance

Wedbush Raises Price Target on Apogee Therapeutics (APGE)  Yahoo Finance

Wedbush Raises Price Target on Apogee Therapeutics (APGE) - Yahoo Finance

Click here to get full coverage on Apogee Therapeutics (APGE) Is Down 7.1% After Positive Yearlong Zumilokibart Data - Has The Bull Case Changed? - sahmcapital.com

Apogee Therapeutics (APGE) Is Down 7.1% After Positive Yearlong Zumilokibart Data - Has The Bull Case Changed?  sahmcapital.com

Apogee Therapeutics (APGE) Is Down 7.1% After Positive Yearlong Zumilokibart Data - Has The Bull Case Changed? - sahmcapital.com

Click here to get full coverage on Apogee Therapeutics (NASDAQ:APGE) Sees Unusually-High Trading Volume on Analyst Upgrade - MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Sees Unusually-High Trading Volume on Analyst Upgrade  MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Sees Unusually-High Trading Volume on Analyst Upgrade - MarketBeat

Click here to get full coverage on Apogee Therapeutics (NASDAQ:APGE) Reaches New 52-Week High - Here's Why - MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Reaches New 52-Week High - Here's Why  MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Reaches New 52-Week High - Here's Why - MarketBeat

Click here to get full coverage on $APGE stock is up 18% today. Here's what we see in our data. - Quiver Quantitative

$APGE stock is up 18% today. Here's what we see in our data.  Quiver Quantitative

$APGE stock is up 18% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on APGE Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

APGE Stock News Today | Earnings, Events & Price Alerts  Intellectia AI

APGE Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Click here to get full coverage on APGE: Zumilokibart maintained and deepened AD responses at 52 weeks with infrequent dosing - TradingView

APGE: Zumilokibart maintained and deepened AD responses at 52 weeks with infrequent dosing  TradingView

APGE: Zumilokibart maintained and deepened AD responses at 52 weeks with infrequent dosing - TradingView

Click here to get full coverage on Apogee Therapeutics: Two Shots A Year, One Shot At Disruption (NASDAQ:APGE) - Seeking Alpha

Apogee Therapeutics: Two Shots A Year, One Shot At Disruption (NASDAQ:APGE)  Seeking Alpha

Apogee Therapeutics: Two Shots A Year, One Shot At Disruption (NASDAQ:APGE) - Seeking Alpha

Click here to get full coverage on Apogee Therapeutics (NASDAQ:APGE) Trading Down 6.5% - What's Next? - MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Trading Down 6.5% - What's Next?  MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Trading Down 6.5% - What's Next? - MarketBeat

Click here to get full coverage on Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis - Slideshow (NASDAQ:APGE) 2026-03-23 - Seeking Alpha

Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis - Slideshow (NASDAQ:APGE) 2026-03-23  Seeking Alpha

Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis - Slideshow (NASDAQ:APGE) 2026-03-23 - Seeking Alpha

Click here to get full coverage on APGE Stock Price and Chart — NASDAQ:APGE - TradingView

APGE Stock Price and Chart — NASDAQ:APGE  TradingView

APGE Stock Price and Chart — NASDAQ:APGE - TradingView

Click here to get full coverage on Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $125.00 - MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $125.00  MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $125.00 - MarketBeat

Click here to get full coverage on Apogee seeks $300M to fund clinical trials and manufacturing - stocktitan.net

Apogee seeks $300M to fund clinical trials and manufacturing  stocktitan.net

Apogee seeks $300M to fund clinical trials and manufacturing - stocktitan.net

Click here to get full coverage on One-year atopic dermatitis trial data land Monday from Apogee - stocktitan.net

One-year atopic dermatitis trial data land Monday from Apogee  stocktitan.net

One-year atopic dermatitis trial data land Monday from Apogee - stocktitan.net

Click here to get full coverage on Apogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 Milestone (APGE) - Seeking Alpha

Apogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 Milestone (APGE)  Seeking Alpha

Apogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 Milestone (APGE) - Seeking Alpha

Click here to get full coverage on Apogee Therapeutics Prices 5.75 Million-Share Offering at $70, Expecting $377.4 Million Net - TradingView

Apogee Therapeutics Prices 5.75 Million-Share Offering at $70, Expecting $377.4 Million Net  TradingView

Apogee Therapeutics Prices 5.75 Million-Share Offering at $70, Expecting $377.4 Million Net - TradingView

Click here to get full coverage on Apogee Therapeutics, Inc. Prices Public Offering of 5 Million Shares at $70.00 Per Share, Anticipating $350 Million in Gross Proceeds - Quiver Quantitative

Apogee Therapeutics, Inc. Prices Public Offering of 5 Million Shares at $70.00 Per Share, Anticipating $350 Million in Gross Proceeds  Quiver Quantitative

Apogee Therapeutics, Inc. Prices Public Offering of 5 Million Shares at $70.00 Per Share, Anticipating $350 Million in Gross Proceeds - Quiver Quantitative

Click here to get full coverage on Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $160.00 at Guggenheim - MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $160.00 at Guggenheim  MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $160.00 at Guggenheim - MarketBeat

Click here to get full coverage on End of Apogee (APGE) Drug Collaboration Leads to Revised Analyst Expectations - Yahoo Finance

End of Apogee (APGE) Drug Collaboration Leads to Revised Analyst Expectations  Yahoo Finance

End of Apogee (APGE) Drug Collaboration Leads to Revised Analyst Expectations - Yahoo Finance

Click here to get full coverage on Why Did Apogee Therapeutics Stock (APGE) Soar Today? - TipRanks

Why Did Apogee Therapeutics Stock (APGE) Soar Today?  TipRanks

Why Did Apogee Therapeutics Stock (APGE) Soar Today? - TipRanks

Click here to get full coverage on BTIG Reiterates 'Buy' Rating for Apogee Therapeutics (APGE) with $137 PT | APGE Stock News - GuruFocus

BTIG Reiterates 'Buy' Rating for Apogee Therapeutics (APGE) with $137 PT | APGE Stock News  GuruFocus

BTIG Reiterates 'Buy' Rating for Apogee Therapeutics (APGE) with $137 PT | APGE Stock News - GuruFocus

Click here to get full coverage on Here is Why Apogee Therapeutics (APGE) Appears Attractive - Yahoo Finance

Here is Why Apogee Therapeutics (APGE) Appears Attractive  Yahoo Finance

Here is Why Apogee Therapeutics (APGE) Appears Attractive - Yahoo Finance

Click here to get full coverage on Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $130.00 - MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $130.00  MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $130.00 - MarketBeat

Click here to get full coverage on APGE: Zumilokibart delivers deep, sustained efficacy and reduced dosing in atopic dermatitis - TradingView

APGE: Zumilokibart delivers deep, sustained efficacy and reduced dosing in atopic dermatitis  TradingView

APGE: Zumilokibart delivers deep, sustained efficacy and reduced dosing in atopic dermatitis - TradingView

Click here to get full coverage on Apogee Therapeutics (Nasdaq: APGE) reports durable 52-week AD results for zumilokibart - stocktitan.net

Apogee Therapeutics (Nasdaq: APGE) reports durable 52-week AD results for zumilokibart  stocktitan.net

Apogee Therapeutics (Nasdaq: APGE) reports durable 52-week AD results for zumilokibart - stocktitan.net

Click here to get full coverage on Apogee Therapeutics' (APGE) Buy Rating Reiterated at BTIG Research - MarketBeat

Apogee Therapeutics' (APGE) Buy Rating Reiterated at BTIG Research  MarketBeat

Apogee Therapeutics' (APGE) Buy Rating Reiterated at BTIG Research - MarketBeat

Click here to get full coverage on Understanding the Setup: (APGE) and Scalable Risk - Stock Traders Daily

Understanding the Setup: (APGE) and Scalable Risk  Stock Traders Daily

Understanding the Setup: (APGE) and Scalable Risk - Stock Traders Daily

Click here to get full coverage on Apogee Therapeutics (APGE) CEO sells 20,000 shares in pre-set 10b5-1 plan - stocktitan.net

Apogee Therapeutics (APGE) CEO sells 20,000 shares in pre-set 10b5-1 plan  stocktitan.net

Apogee Therapeutics (APGE) CEO sells 20,000 shares in pre-set 10b5-1 plan - stocktitan.net

Click here to get full coverage on Assessing Apogee Therapeutics (APGE) Valuation After Positive Phase 1b Asthma Trial Data And 2026 Pipeline Milestones - Yahoo Finance

Assessing Apogee Therapeutics (APGE) Valuation After Positive Phase 1b Asthma Trial Data And 2026 Pipeline Milestones  Yahoo Finance

Assessing Apogee Therapeutics (APGE) Valuation After Positive Phase 1b Asthma Trial Data And 2026 Pipeline Milestones - Yahoo Finance

Click here to get full coverage on $APGE stock is down 12% today. Here's what we see in our data. | APGE Stock News - Quiver Quantitative

$APGE stock is down 12% today. Here's what we see in our data. | APGE Stock News  Quiver Quantitative

$APGE stock is down 12% today. Here's what we see in our data. | APGE Stock News - Quiver Quantitative

Click here to get full coverage on Why Did APGE Stock Jump 22% Today? - Stocktwits

Why Did APGE Stock Jump 22% Today?  Stocktwits

Why Did APGE Stock Jump 22% Today? - Stocktwits

Click here to get full coverage on Craig-Hallum Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Cuts Target Price to $114 - 富途牛牛

Craig-Hallum Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Cuts Target Price to $114  富途牛牛

Craig-Hallum Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Cuts Target Price to $114 - 富途牛牛

Click here to get full coverage on Wedbush raises price target on Apogee Therapeutics (APGE) - MSN

Wedbush raises price target on Apogee Therapeutics (APGE)  MSN

Wedbush raises price target on Apogee Therapeutics (APGE) - MSN

Click here to get full coverage on APGE Stock On The Rise as Analyst Upgrades Predict Growth - StocksToTrade

APGE Stock On The Rise as Analyst Upgrades Predict Growth  StocksToTrade

APGE Stock On The Rise as Analyst Upgrades Predict Growth - StocksToTrade

Click here to get full coverage on Apogee Therapeutics (NASDAQ:APGE) Shares Gap Up - Here's Why - MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Shares Gap Up - Here's Why  MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Shares Gap Up - Here's Why - MarketBeat

Click here to get full coverage on APGE: Zumilokibart’s Best-in-Class Atopic Dermatitis Profile and Long-Acting Dosing Support Buy Rating and Re-Rating Potential - TipRanks

APGE: Zumilokibart’s Best-in-Class Atopic Dermatitis Profile and Long-Acting Dosing Support Buy Rating and Re-Rating Potential  TipRanks

APGE: Zumilokibart’s Best-in-Class Atopic Dermatitis Profile and Long-Acting Dosing Support Buy Rating and Re-Rating Potential - TipRanks

Click here to get full coverage on HighVista Strategies LLC Grows Position in Apogee Therapeutics Inc. $APGE - MarketBeat

HighVista Strategies LLC Grows Position in Apogee Therapeutics Inc. $APGE  MarketBeat

HighVista Strategies LLC Grows Position in Apogee Therapeutics Inc. $APGE - MarketBeat

Click here to get full coverage on Apogee Therapeutics to Announce 52-Week Data from Phase 2 APEX Trial of Zumilokibart on March 23, 2026 - Quiver Quantitative

Apogee Therapeutics to Announce 52-Week Data from Phase 2 APEX Trial of Zumilokibart on March 23, 2026  Quiver Quantitative

Apogee Therapeutics to Announce 52-Week Data from Phase 2 APEX Trial of Zumilokibart on March 23, 2026 - Quiver Quantitative

Click here to get full coverage on APGE Shares Rise After Skin Disease Medication Demonstrates Lasting Effectiveness Over 52 Weeks - Bitget

APGE Shares Rise After Skin Disease Medication Demonstrates Lasting Effectiveness Over 52 Weeks  Bitget

APGE Shares Rise After Skin Disease Medication Demonstrates Lasting Effectiveness Over 52 Weeks - Bitget

Click here to get full coverage on Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Average Recommendation of "Moderate Buy" from Analysts  MarketBeat

Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Click here to get full coverage on Fairmount Healthcare Fund II L.P. sells Apogee (APGE) shares for $133.53 million - Investing.com

Fairmount Healthcare Fund II L.P. sells Apogee (APGE) shares for $133.53 million  Investing.com

Fairmount Healthcare Fund II L.P. sells Apogee (APGE) shares for $133.53 million - Investing.com

Click here to get full coverage on Is Apogee Therapeutics Inc. (APGE) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Is Apogee Therapeutics Inc. (APGE) Outperforming Other Medical Stocks This Year?  Yahoo Finance

Is Apogee Therapeutics Inc. (APGE) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Click here to get full coverage on Is Rising R&D Spend And New Equity Shelf Altering The Investment Case For Apogee Therapeutics (APGE)? - Yahoo Finance

Is Rising R&D Spend And New Equity Shelf Altering The Investment Case For Apogee Therapeutics (APGE)?  Yahoo Finance

Is Rising R&D Spend And New Equity Shelf Altering The Investment Case For Apogee Therapeutics (APGE)? - Yahoo Finance

Click here to get full coverage on T. Rowe Price (APGE) holds 6.21M shares, 11.3% stake disclosed - stocktitan.net

T. Rowe Price (APGE) holds 6.21M shares, 11.3% stake disclosed  stocktitan.net

T. Rowe Price (APGE) holds 6.21M shares, 11.3% stake disclosed - stocktitan.net

Click here to get full coverage on BTIG Research Reiterates "Buy" Rating for Apogee Therapeutics (NASDAQ:APGE) - MarketBeat

BTIG Research Reiterates "Buy" Rating for Apogee Therapeutics (NASDAQ:APGE)  MarketBeat

BTIG Research Reiterates "Buy" Rating for Apogee Therapeutics (NASDAQ:APGE) - MarketBeat

Click here to get full coverage on Jefferies Financial Group Inc. Sells 74,273 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat

Jefferies Financial Group Inc. Sells 74,273 Shares of Apogee Therapeutics Inc. $APGE  MarketBeat

Jefferies Financial Group Inc. Sells 74,273 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat

Click here to get full coverage on Apogee Therapeutics (APGE) CMO sells shares under 10b5-1 trading plan - stocktitan.net

Apogee Therapeutics (APGE) CMO sells shares under 10b5-1 trading plan  stocktitan.net

APGE

Price Chart

Key Statistics

Technicals

About APGE

Latest News

Should Apogee Therapeutics’ (APGE) Infrequent-Dosing AD Data and $403M Equity Raise Require Investor Action? - simplywall.st

Mizuho Initiates Coverage of Apogee Therapeutics (APGE) with Outperform Recommendation - MSN

Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $110.00 at Mizuho - MarketBeat

Advanced Charts

Top Gainers

Top Losers